Instil Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TIL Nasdaq 8731 https://instilbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Instil Bio Inc

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 11th, 2023 11:00 am
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Mar 31st, 2023 11:00 am
Here’s Why Instil Bio (TIL) Declined in Q4 - Mar 22nd, 2023 11:57 am
Private equity firms account for 39% of Instil Bio, Inc.'s (NASDAQ:TIL) ownership, while institutions account for 34% - Feb 17th, 2023 12:04 pm
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site - Jan 31st, 2023 10:00 pm
Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers - Jan 9th, 2023 5:30 pm
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer - Jan 9th, 2023 12:00 pm
Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) - Dec 13th, 2022 2:35 pm
Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) - Dec 9th, 2022 2:35 pm
Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees - Dec 8th, 2022 4:04 pm
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce - Dec 8th, 2022 12:00 pm
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 9:07 pm
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting - Nov 8th, 2022 12:00 pm
Instil Bio Share Sink After Enrollment Pause In Cancer Therapy Trials - Oct 31st, 2022 2:40 pm
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing - Oct 31st, 2022 11:00 am
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer - Oct 18th, 2022 11:00 am
Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit - Sep 19th, 2022 11:20 am
Instil Bio to Present at Morgan Stanley Global Healthcare Conference - Sep 9th, 2022 11:00 am
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer - Sep 6th, 2022 11:00 am
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Aug 12th, 2022 11:00 am